| scholarly article | Q13442814 |
| P50 | author | Caroline Dive | Q30119872 |
| Alison Backen | Q117194598 | ||
| Juan Valle | Q37830751 | ||
| David Cunningham | Q38803238 | ||
| Srinivasan Madhusudan | Q56435835 | ||
| P2093 | author name string | Justin S Waters | |
| Paul J Ross | |||
| Daniel H Palmer | |||
| D Alan Anthoney | |||
| Anthony Maraveyas | |||
| Harpreet Wasan | |||
| Charlotte Rees | |||
| Will P Steward | |||
| Karen Morris | |||
| Andre Lopes | |||
| Marian Duggan | |||
| Pippa Corrie | |||
| John A Bridgewater | |||
| Sandy Beare | |||
| P2860 | cites work | Mechanism of action and in vivo role of platelet-derived growth factor | Q22010594 |
| AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
| A novel high-through-put assay for screening of pro-apoptotic drugs | Q31105814 | ||
| Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | Q33390747 | ||
| Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial | Q33620083 | ||
| Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States | Q33949931 | ||
| Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study | Q34048813 | ||
| ‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use | Q58282597 | ||
| Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells | Q73075671 | ||
| Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas | Q78204868 | ||
| Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma | Q80075002 | ||
| Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance | Q82499254 | ||
| Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer | Q34063503 | ||
| A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. | Q34241985 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study | Q34623625 | ||
| Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells. | Q35060289 | ||
| Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis | Q35711843 | ||
| Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer | Q36385291 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study | Q36720049 | ||
| Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In | Q37132598 | ||
| Serum tumor markers in bile duct cancer--a review. | Q38214343 | ||
| Targeting PDGFR-β in Cholangiocarcinoma | Q39434606 | ||
| Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy | Q39665887 | ||
| Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study | Q43237133 | ||
| Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors | Q43430750 | ||
| Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? | Q44022677 | ||
| Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas | Q44660500 | ||
| Apoptosis generates stable fragments of human type I keratins | Q44865350 | ||
| A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. | Q45045994 | ||
| Optimisation of circulating biomarkers of cell death for routine clinical use. | Q47884494 | ||
| Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. | Q48001140 | ||
| Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme | Q48058166 | ||
| Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. | Q55043149 | ||
| Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma | Q57569583 | ||
| Circulating biomarkers in hepatocellular carcinoma | Q58282111 | ||
| Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer | Q58282332 | ||
| Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer | Q58282415 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| cisplatin | Q412415 | ||
| chemotherapy | Q974135 | ||
| ??? | Q18556397 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 967-978 | |
| P577 | publication date | 2015-07-12 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial | |
| P478 | volume | 16 |
| Q95843571 | A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer |
| Q35934963 | A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study |
| Q64134451 | A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma |
| Q60961748 | Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: A case report and literature review |
| Q39289707 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications |
| Q60927301 | Biliary tract cancer: current challenges and future prospects |
| Q64101426 | Biliary tract cancers: current knowledge, clinical candidates and future challenges |
| Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
| Q34520190 | Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. |
| Q85605167 | Chemotherapy and antiangiogenics in biliary tract cancer |
| Q36107068 | Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials |
| Q96817624 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
| Q89170919 | Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial |
| Q97419371 | Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience |
| Q92591396 | Contemporary Tailored Oncology Treatment of Biliary Tract Cancers |
| Q40824695 | Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy |
| Q38830071 | Current Progress in Immunotherapy for the Treatment of Biliary Cancers |
| Q39453572 | Current biologics for treatment of biliary tract cancers |
| Q53814608 | Diagnosis and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. |
| Q33440859 | Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials |
| Q33436600 | Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis |
| Q38642455 | Emerging molecular targets and therapy for cholangiocarcinoma |
| Q37631655 | From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers |
| Q55481891 | Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. |
| Q57211742 | Gemcitabine-based chemotherapy for advanced biliary tract carcinomas |
| Q39040859 | HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? |
| Q38703148 | Immunotherapeutic Approaches to Biliary Cancer |
| Q39186928 | Intrahepatic cholangiocarcinoma: current management and emerging therapies |
| Q92251015 | Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016 |
| Q47429093 | MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma |
| Q39385781 | Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells |
| Q39521003 | Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients |
| Q64085995 | Molecular Pathogenesis of Cholangiocarcinoma |
| Q92029922 | Molecular targets in cholangiocarcinoma |
| Q38619219 | New Horizons for Precision Medicine in Biliary Tract Cancers |
| Q90308323 | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma |
| Q54476966 | New molecular and immunotherapeutic approaches in biliary cancer. |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q37305538 | Pediatric Kawasaki Disease and Adult Human Immunodeficiency Virus Kawasaki-Like Syndrome Are Likely the Same Malady |
| Q58599860 | Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer |
| Q48214785 | Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer. |
| Q48203761 | Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. |
| Q57118798 | Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) |
| Q60910477 | Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program |
| Q57463236 | Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases |
| Q92460033 | Second-line therapies in advanced biliary tract cancers |
| Q33688577 | Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. |
| Q50526996 | Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. |
| Q49627919 | Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma |
| Q64249982 | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| Q30398807 | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option |
| Q60922992 | The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis |
| Q92703974 | The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis |
| Q37393508 | The Wnt/β-catenin signaling pathway mechanism for pancreatic cancer chemoresistance in a three-dimensional cancer microenvironment |
| Q47139810 | The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis |
| Q26751224 | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets |
| Q33656860 | The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer |
| Q33621529 | Therapeutic options for intrahepatic cholangiocarcinoma |
| Q57073983 | Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report |
| Q90045641 | Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study |
Search more.